Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zymolytic grain based extract (ZGE) is a nutraceutical product derived from the enzymatic fermentation of grains. It has demonstrated antiviral activity against HIV-1 in vitro and in vivo, with low cytotoxicity. Additionally, ZGE exhibits antioxidant properties and may have anti-obesity effects as well as the ability to extend lifespan and enhance stress resistance in model organisms such as Caenorhabditis elegans. The bioactive components are believed to include phenolic compounds and other phytochemicals generated or enriched during the fermentation process[1][4]. Its mechanism of action is not fully elucidated but appears to involve inhibition of viral infection (HIV-1), antioxidative effects, and metabolic modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zymolytic grain based extract.